316 related articles for article (PubMed ID: 11459281)
1. Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.
Kozuch P; Petryk M; Evans A; Bruckner HW
Surg Clin North Am; 2001 Jun; 81(3):683-90. PubMed ID: 11459281
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Kozuch P; Petryk M; Bruckner HW
Hematol Oncol Clin North Am; 2002 Feb; 16(1):123-38. PubMed ID: 12063823
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for advanced pancreatic cancer.
Haller DG
Int J Radiat Oncol Biol Phys; 2003; 56(4 Suppl):16-23. PubMed ID: 12826247
[TBL] [Abstract][Full Text] [Related]
4. [The update on pancreatic cancer chemotherapy].
Brasiūniene B; Juozaityte E; Brasiūnas V; Inciūra A
Medicina (Kaunas); 2003; 39(10):1016-25. PubMed ID: 14578647
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan and fixed-dose-rate gemcitabine in advanced pancreatic and biliary cancer: phase I study.
Sun W; Haller D
Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):16-9. PubMed ID: 14569842
[TBL] [Abstract][Full Text] [Related]
6. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
Stathopoulos GP; Syrigos K; Aravantinos G; Polyzos A; Papakotoulas P; Fountzilas G; Potamianou A; Ziras N; Boukovinas J; Varthalitis J; Androulakis N; Kotsakis A; Samonis G; Georgoulias V
Br J Cancer; 2006 Sep; 95(5):587-92. PubMed ID: 16909140
[TBL] [Abstract][Full Text] [Related]
7. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract][Full Text] [Related]
8. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
Ulrich-Pur H; Raderer M; Verena Kornek G; Schüll B; Schmid K; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Scheithauer W
Br J Cancer; 2003 Apr; 88(8):1180-4. PubMed ID: 12698181
[TBL] [Abstract][Full Text] [Related]
10. Palliative chemotherapy for pancreatic malignancies.
Mehta SP
Surg Clin North Am; 2010 Apr; 90(2):365-75. PubMed ID: 20362792
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Heinemann V
Semin Oncol; 2002 Dec; 29(6 Suppl 20):9-16. PubMed ID: 12577228
[TBL] [Abstract][Full Text] [Related]
12. [Chemoradiation for pancreatic adenocarcinoma].
Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C
Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252
[TBL] [Abstract][Full Text] [Related]
13. [Gemcitabine-based combinations in inoperable pancreatic cancers].
Louvet C; André T; Artru P
Bull Cancer; 2002 Aug; 89 Spec No():S96-101. PubMed ID: 12449038
[TBL] [Abstract][Full Text] [Related]
14. MM-398 achieves primary endpoint of overall survival in phase III study in patients with gemcitabine refractory metastatic pancreatic cancer.
Saif MW
JOP; 2014 May; 15(3):278-9. PubMed ID: 24865544
[No Abstract] [Full Text] [Related]
15. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Lamb YN; Scott LJ
Drugs; 2017 May; 77(7):785-792. PubMed ID: 28401446
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapeutic gemcitabine doublets in pancreatic carcinoma.
Richards DA
Semin Oncol; 2005 Aug; 32(4 Suppl 6):S9-13. PubMed ID: 16143162
[TBL] [Abstract][Full Text] [Related]
17. Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.
Rocha Lima CM; Eckardt JR; Leong SS; Sherman CA; Perkel JA; Putman T; Safa AR; Bahadori HR; Green MR
Semin Oncol; 1999 Oct; 26(5 Suppl 16):43-50; discussion 71-2. PubMed ID: 10585008
[TBL] [Abstract][Full Text] [Related]
18. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Gourgou-Bourgade S; Bascoul-Mollevi C; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Boige V; Bérille J; Conroy T
J Clin Oncol; 2013 Jan; 31(1):23-9. PubMed ID: 23213101
[TBL] [Abstract][Full Text] [Related]
19. Current and future strategies for treating metastatic pancreatic cancer.
Berlin JD
Clin Adv Hematol Oncol; 2004 Aug; 2(8):510-2. PubMed ID: 16163230
[No Abstract] [Full Text] [Related]
20. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
